Dr Susan Galbraith at ESMO 2014: Phase I/II AURA study of the EGFR inhibitor, AZD9291, in advanced NSCLC

EMJ has 458 videos Subscribe Here

Description: At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the ongoing phase I/II AURA study of the epidermal growth factor receptor (EGFR) inhibitor, AZD9291, in patients with advanced non-small cell lung cancer (NSCLC) and disease progression while on a previous continuous treatment with an EGFR inhibitor.
Shared By : EMJ
Posted on : 01/15/15
Added : 3 years ago


Nothing found.

More From EMJ

Nothing found.